BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36174444)

  • 21. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
    Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
    J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The microsomal enzyme 17β-hydroxysteroid dehydrogenase 3 faces the cytoplasm and uses NADPH generated by glucose-6-phosphate dehydrogenase.
    Legeza B; Balázs Z; Nashev LG; Odermatt A
    Endocrinology; 2013 Jan; 154(1):205-13. PubMed ID: 23183177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
    Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Pharmacokinetics, Tissue Distribution and Primary Safety Evaluation of a Novel Curcumin Analogue H10 Suspension, a Potential 17β Hydroxysteroid Dehydrogenase Type 3 Inhibitor.
    Xiao L; Bei Y; Li J; Chen M; Zhang Y; Xiang Q
    Chem Pharm Bull (Tokyo); 2021 Jan; 69(1):52-58. PubMed ID: 33087639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
    Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
    Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.
    Hu GX; Zhao B; Chu Y; Li XH; Akingbemi BT; Zheng ZQ; Ge RS
    Int J Androl; 2011 Apr; 34(2):138-44. PubMed ID: 20522127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
    Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
    Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical analyses and molecular modeling explain the functional loss of 17β-hydroxysteroid dehydrogenase 3 mutant G133R in three Tunisian patients with 46, XY Disorders of Sex Development.
    Engeli RT; Rhouma BB; Sager CP; Tsachaki M; Birk J; Fakhfakh F; Keskes L; Belguith N; Odermatt A
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):147-54. PubMed ID: 26545797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
    Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
    Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
    Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
    Maltais R; Trottier A; Roy J; Ayan D; Bertrand N; Poirier D
    J Steroid Biochem Mol Biol; 2018 Apr; 178():167-176. PubMed ID: 29248731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.